Literature DB >> 11705059

Primary hepatocellular carcinoma in Ile-Ife, Nigeria: a prospective study of 154 cases.

D A Ndububa1, O S Ojo, O O Adeodu, V A Adetiloye, B J Olasode, O C Famurewa, M A Durosinmi, A E Agbakwuru.   

Abstract

Primary hepatocellular carcinoma is a tumour with a dismal prognosis. In recent times, however, great advances have been made in its management. This 13-year prospective study done at Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, was an attempt to appraise the outlook of the disease in Nigeria at the turn of the 21st century. Primary hepatocellular carcinoma affected mainly middle-aged Nigerians (peak age-group = 40-59 years), predominantly males (M:F = 2:1) and, in a sizeable proportion (78%), it co-existed with cirrhosis. Significant risk factors found were scarification marks (87%), anicteric hepatitis (71.3%), abuse of medicinal herbs and analgesics (68.6%) and injection from quack doctors (51%). Blood test for HBsAg was positive in 61% of patients. The mean duration of symptoms. before diagnosis was 12.64 weeks (SD 13.77) while, on the average, patients died within 14.0 weeks (SD 13.0) of illness, usually of liver failure (67.7%). Only symptomatic treatment could be offered in 148 patients (96.1%) while chemotherapy was merely attempted in 5 (3.25%). Majority of the patients (59.8%) were either discharged against medical advice or lost to follow-up. This study shows that Nigerian patients presenting with primary hepatocellular carcinoma already have advanced disease and this makes treatment and survival hopeless. Universal immunisation with HB vaccine should be implemented in Nigeria without further delay and health education should be directed against socio-cultural practices which are aetiological risk factors for primary hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2001        PMID: 11705059

Source DB:  PubMed          Journal:  Niger J Med        ISSN: 1115-2613


  8 in total

1.  Hepatitis B Infection: A Mixed Methods of Disclosure Pattern and Social Problems in the Nigerian Family.

Authors:  Olusegun Adekanle; Akinwumi Oluwole Komolafe; Samuel A Olowookere; Oluwasegun Ijarotimi; Dennis Amajuoyi Ndububa
Journal:  J Patient Exp       Date:  2019-03-07

2.  Chronic hepatitis B: management challenges in resource-poor countries.

Authors:  Sylvester Chuks Nwokediuko
Journal:  Hepat Mon       Date:  2011-10       Impact factor: 0.660

3.  Knowledge of Hepatitis B Virus Infection, Immunization with Hepatitis B Vaccine, Risk Perception, and Challenges to Control Hepatitis among Hospital Workers in a Nigerian Tertiary Hospital.

Authors:  Olusegun Adekanle; Dennis A Ndububa; Samuel Anu Olowookere; Oluwasegun Ijarotimi; Kayode Thaddeus Ijadunola
Journal:  Hepat Res Treat       Date:  2015-01-22

4.  THE PREVALENCE LIVER FUNCTION AND IMMUNOLOGIC STATUS OF CHILDREN WITH HIV AND HEPATITIS B VIRUS COINFECTION IN ENUGU, NIGERIA.

Authors:  Uleanya Nwachinemere Davidson; Nwokoye Ikenna Chidiebele; Emodi Ifeoma Josephine; Obidike Egbuna Olakunle; Ikefuna Anthony Nnaemeka; Eze Jude Chijioke; Ndu Ikenna Kingsley
Journal:  Afr J Infect Dis       Date:  2016-05-01

5.  The state of adolescent immunization in Nigeria: a wake up call for all stakeholders.

Authors:  Folusho Mubowale Balogun
Journal:  Pan Afr Med J       Date:  2019-08-13

6.  Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma.

Authors:  Olufemi Michael Soyemi; Jesse Abiodun Otegbayo; Samuel Olawale Ola; Adegboyega Akere; Temitope Soyemi
Journal:  BMC Res Notes       Date:  2012-08-03

7.  Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study.

Authors:  Akpakip I Ette; Dennis A Ndububa; Olusegun Adekanle; Udeme Ekrikpo
Journal:  BMC Gastroenterol       Date:  2015-09-04       Impact factor: 3.067

8.  Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting.

Authors:  Hyasinta Jaka; Stephen E Mshana; Peter F Rambau; Nestory Masalu; Phillipo L Chalya; Samuel E Kalluvya
Journal:  World J Surg Oncol       Date:  2014-08-02       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.